| Entry |
|
|---|
| Name |
Rilmazafone hydrochloride hydrate (JP18);
Rilmazafone hydrochloride dihydrate;
Rilmazafone hydrochloride;
Rhythmy (TN) |
|---|
| Formula |
C21H20Cl2N6O3. 2H2O. HCl
|
|---|
| Exact mass |
546.0952
|
|---|
| Mol weight |
547.8194
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01835 Benzodiazepine sedative-hypnotics
DG03202 Hypnotic
DG01567 GABA-A receptor agonist
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02970 CES substrate
|
|---|
| Remark |
| Therapeutic category: | 1129 |
| Product (DG01307): | D01564<JP> |
|
|---|
| Efficacy |
Sedative-hypnotic |
|---|
| Comment |
Benzodiazepines
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07230 | GABA-A receptor agonists/antagonists |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
112 Hypnotics and sedatives, anxiolytics
1129 Others
D01564 Rilmazafone hydrochloride hydrate (JP18)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01835 Benzodiazepine sedative-hypnotics
DG01307 Rilmazafone
D01564 Rilmazafone hydrochloride hydrate
DG03202 Hypnotic
DG01307 Rilmazafone
D01564 Rilmazafone hydrochloride hydrate
DG01567 GABA-A receptor agonist
DG01307 Rilmazafone
D01564 Rilmazafone hydrochloride hydrate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01307 Rilmazafone
D01564 Rilmazafone hydrochloride hydrate
DG02970 CES substrate
DG01307 Rilmazafone
D01564 Rilmazafone hydrochloride hydrate
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03202 Hypnotic
D01564 Rilmazafone hydrochloride hydrate
Target-based classification of drugs [BR:br08310]
Ion channels
Ligand-gated ion channels
GABA (ionotropic)
GABR
D01564 Rilmazafone hydrochloride hydrate (JP18) <JP>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01564 Rilmazafone hydrochloride hydrate
D01564 Rilmazafone hydrochloride tablets
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01564
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01835 Benzodiazepine sedative-hypnotics
DG01307 Rilmazafone
DG03202 Hypnotic
DG01307 Rilmazafone
DG01567 GABA-A receptor agonist
DG01307 Rilmazafone
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01307 Rilmazafone
DG02970 CES substrate
DG01307 Rilmazafone
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 35
1 N4y N 31.6779 -17.6593
2 C8y C 30.5348 -18.4801
3 N5x N 30.9600 -19.8196
4 C8y C 32.3658 -19.8243
5 N5x N 32.8005 -18.4879
6 C8y C 31.6784 -16.2592
7 C8y C 32.8916 -15.5668
8 C8x C 32.8987 -14.1630
9 C8y C 31.6926 -13.4514
10 C8x C 30.4722 -14.1506
11 C8x C 30.4652 -15.5546
12 C1b C 29.3037 -17.8094
13 C5a C 33.1887 -20.9594
14 O5a O 32.6102 -22.2412
15 C1a C 35.4036 -22.0964
16 N1c N 34.5854 -20.9570
17 C1a C 35.1593 -19.6834
18 X Cl 31.7016 -12.0545
19 C5a C 34.0978 -16.2714
20 O5a O 34.0909 -17.6681
21 C8y C 35.3111 -15.5790
22 C8x C 36.5126 -16.2896
23 C8x C 37.7258 -15.5973
24 C8x C 37.7329 -14.2004
25 C8x C 36.5267 -13.4959
26 C8y C 35.3135 -14.1882
27 N1b N 28.1104 -18.5353
28 C5a C 26.8850 -17.8648
29 O5a O 26.8529 -16.4684
30 C1b C 25.6915 -18.5909
31 N1a N 24.4661 -17.9204
32 X Cl 34.0978 -13.4828
33 X Cl 40.4905 -20.0243
34 O0 O 41.0440 -17.4895
35 O0 O 41.0440 -17.4895
BOND 34
1 4 13 1
2 1 6 1
3 16 17 1
4 9 18 1
5 7 19 1
6 19 20 2
7 2 3 2
8 19 21 1
9 1 2 1
10 3 4 1
11 4 5 2
12 5 1 1
13 2 12 1
14 21 22 2
15 22 23 1
16 23 24 2
17 24 25 1
18 25 26 2
19 26 21 1
20 6 7 2
21 12 27 1
22 7 8 1
23 27 28 1
24 8 9 2
25 28 29 2
26 9 10 1
27 28 30 1
28 10 11 2
29 30 31 1
30 11 6 1
31 26 32 1
32 13 14 2
33 15 16 1
34 16 13 1
BRACKET 1 38.7800 -18.4800 38.7800 -16.5200
1 41.5800 -16.5200 41.5800 -18.4800
1 2
ORIGINAL 1 34
REPEAT 1 35
|
|---|
